Zurovac Dejan, Ndhlovu Mickey, Sipilanyambe Nawa, Chanda Pascalina, Hamer Davidson H, Simon Jon L, Snow Robert W
Malaria Public Health and Epidemiology Group, Centre for Geographic Medicine, KEMRI/Wellcome Trust Collaborative Programme, Nairobi, Kenya.
Malar J. 2007 Mar 16;6:31. doi: 10.1186/1475-2875-6-31.
BACKGROUND: Zambia was the first African country to change national antimalarial treatment policy to artemisinin-based combination therapy--artemether-lumefantrine. An evaluation during the early implementation phase revealed low readiness of health facilities and health workers to deliver artemether-lumefantrine, and worryingly suboptimal treatment practices. Improvements in the case-management of uncomplicated malaria two years after the initial evaluation and three years after the change of policy in Zambia are reported. METHODS: Data collected during the health facility surveys undertaken in 2004 and 2006 at all outpatient departments of government and mission facilities in four Zambian districts were analysed. The surveys were cross-sectional, using a range of quality of care assessment methods. The main outcome measures were changes in health facility and health worker readiness to deliver artemether-lumefantrine, and changes in case-management practices for children below five years of age presenting with uncomplicated malaria as defined by national guidelines. RESULTS: In 2004, 94 health facilities, 103 health workers and 944 consultations for children with uncomplicated malaria were evaluated. In 2006, 104 facilities, 135 health workers and 1125 consultations were evaluated using the same criteria of selection. Health facility and health worker readiness improved from 2004 to 2006: availability of artemether-lumefantrine from 51% (48/94) to 60% (62/104), presence of artemether-lumefantrine dosage wall charts from 20% (19/94) to 75% (78/104), possession of guidelines from 58% (60/103) to 92% (124/135), and provision of in-service training from 25% (26/103) to 41% (55/135). The proportions of children with uncomplicated malaria treated with artemether-lumefantrine also increased from 2004 to 2006: from 1% (6/527) to 27% (149/552) in children weighing 5 to 9 kg, and from 11% (42/394) to 42% (231/547) in children weighing 10 kg or more. In both weight groups and both years, 22% (441/2020) of children with uncomplicated malaria were not prescribed any antimalarial drug. CONCLUSION: Although significant improvements in malaria case-management have occurred over two years in Zambia, the quality of treatment provided at the point of care is not yet optimal. Strengthening weak health systems and improving the delivery of effective interventions should remain high priority in all countries implementing new treatment policies for malaria.
背景:赞比亚是首个将国家抗疟治疗政策改为以青蒿素为基础的联合疗法——蒿甲醚-本芴醇的非洲国家。在早期实施阶段的一项评估显示,卫生设施和卫生工作者在提供蒿甲醚-本芴醇方面准备不足,且令人担忧的是治疗方法并不理想。本文报告了赞比亚在初始评估两年后以及政策变更三年后,单纯性疟疾病例管理方面的改善情况。 方法:对2004年和2006年在赞比亚四个地区的政府和教会设施的所有门诊部门进行的卫生设施调查中收集的数据进行分析。这些调查为横断面调查,采用了一系列护理质量评估方法。主要结果指标为卫生设施和卫生工作者在提供蒿甲醚-本芴醇方面的准备情况变化,以及按照国家指南定义的单纯性疟疾患儿病例管理做法的变化。 结果:2004年,对94个卫生设施、103名卫生工作者以及944例单纯性疟疾患儿的会诊进行了评估。2006年,使用相同的选择标准对104个设施、135名卫生工作者以及1125例会诊进行了评估。从2004年到2006年,卫生设施和卫生工作者的准备情况有所改善:蒿甲醚-本芴醇的可获得性从51%(48/94)提高到60%(62/104),蒿甲醚-本芴醇剂量挂图的配备从20%(19/94)提高到75%(78/104),指南的拥有率从58%(60/103)提高到92%(124/135),在职培训的提供率从25%(26/103)提高到41%(55/135)。接受蒿甲醚-本芴醇治疗的单纯性疟疾患儿比例在2004年到2006年也有所增加:体重5至9千克的患儿从1%(6/527)增至27%(149/552),体重10千克及以上的患儿从11%(42/394)增至42%(231/547)。在这两个体重组以及这两年中,22%(441/2020)的单纯性疟疾患儿未开具任何抗疟药物。 结论:尽管赞比亚在两年内疟疾病例管理方面有显著改善,但医疗现场提供的治疗质量仍未达到最佳。在所有实施疟疾新治疗政策的国家,加强薄弱的卫生系统并改善有效干预措施的提供应仍是高度优先事项。
Malar J. 2017-4-26
Health Res Policy Syst. 2016-6-1
Health Policy Plan. 2004-11
Lancet. 2004-1-3